# A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects

> **NCT01610388** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 61 (actual)

## Conditions studied

- Infections, Bacterial

## Interventions

- **DRUG:** 500mg IV GSK1322322/placebo
- **DRUG:** 1000mg oral GSK1322322/placebo
- **DRUG:** 1000mg IV GSK1322322/placebo
- **DRUG:** 1500mg oral GSK1322322/placebo dose
- **DRUG:** 1500mg IV GSK1322322/placebo
- **DRUG:** 2000mg IV GSK1322322J/placebo
- **DRUG:** 3000mg IV GSK1322322J/placebo
- **DRUG:** 1000mg IV GSK1322322J/placebo

## Key facts

- **NCT ID:** NCT01610388
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-13
- **Primary completion:** 2012-01-26
- **Final completion:** 2012-01-26
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2017-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01610388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01610388, "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT01610388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*